CAS 923032-37-5

Refametinib

Description:

Refametinib is a small molecule inhibitor primarily targeting the mitogen-activated protein kinase (MAPK) pathway, specifically the MEK1 and MEK2 enzymes. It is classified as an experimental anticancer agent and has been investigated for its potential in treating various types of malignancies, particularly those with RAS mutations. Refametinib exhibits a selective mechanism of action, which helps to minimize off-target effects commonly associated with broader-spectrum kinase inhibitors. The compound is typically administered orally and has shown promise in clinical trials, demonstrating efficacy in inhibiting tumor growth and progression. Its pharmacokinetic properties include moderate bioavailability and a relatively short half-life, necessitating careful dosing regimens. Additionally, refametinib's safety profile includes potential adverse effects such as rash, diarrhea, and fatigue, which are common with targeted therapies. Ongoing research continues to explore its effectiveness in combination with other therapeutic agents to enhance treatment outcomes in cancer patients.

Formula: C₁₉H₂₀F₃IN₂O₅S

InChI: InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1

InChI key: InChIKey=RDSACQWTXKSHJT-NSHDSACASA-N

SMILES: S(NC1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1OC)(=O)(=O)C3(C[C@@H](CO)O)CC3

Synonyms:

• N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropanesulfonamide
• BAY 8697661
• RDEA 119
• Cyclopropanesulfonamide, N-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-
• BAY 869766
• BAY 869766; BAY 86-9766
• RDEA119
• Lorlatinib
• RDEA119 USP/EP/BP
• RefaMetinib/BAY 8697661
• Refametinib (BAY86-9766)
• (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
• CS-2434
• RefaMetinib
• N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
• REFAMETINIB(RDEA119)
• BAY 869766;BAY 86-97661;RDEA119

RDEA119

CAS: 923032-37-5

Formula: C₁₉H₂₀F₃IN₂O₅S

Purity: 99%

Color and Shape: Solid

Molecular weight: 572.3372

Ref: IN-DA00GRCO

Refametinib

CAS: 923032-37-5

Refametinib

Purity: ≥98%

Molecular weight: 572.34g/mol

Ref: 54-BUP12219

Refametinib

CAS: 923032-37-5

Refametinib

Purity: 99%

Molecular weight: 572.34g/mol

Ref: 54-BISN0230

Refametinib

CAS: 923032-37-5

Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).

Formula: C₁₉H₂₀F₃IN₂O₅S

Purity: 99.85% - >99.99%

Color and Shape: Solid

Molecular weight: 572.34

Ref: TM-T6636

Refametinib

CAS: 923032-37-5

Purity: 99%

Molecular weight: 572.009

Ref: 10-F859287

Refametinib

CAS: 923032-37-5

Inhibitor of MEK1 and MEK2 kinases

Formula: C₁₉H₂₀F₃IN₂O₅S

Purity: Min. 95%

Molecular weight: 572.34 g/mol

Ref: 3D-FR104239